Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9%
Management Admin

Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform

By The Northwire Desk — AI Analysis Jun 12, 2026 · 07:10 PAIN · 1.89 Vector Science and Therapeutics Corp.
PAIN · Price

Executive Summary

  • Vector Science & Therapeutics appointed former MLB star Dexter Fowler as Chief Athletic Officer for Valor, its newly positioned sports medicine division.
  • Fowler will lead athlete engagement, onboarding, and advisory functions for the division's transdermal peptide platform focused on soft tissue repair and recovery.
  • The appointment leverages Fowler's professional sports credibility to bridge the gap between elite athletes and the sports medicine community.

Key Details

  • Appointment: Dexter Fowler named Chief Athletic Officer for Valor (Vector's sports medicine division) and Chair of the Athlete Advisory Board.
  • Fowler's Background: 14-year MLB veteran (Colorado Rockies, Houston Astros, Chicago Cubs, St. Louis Cardinals, Los Angeles Angels), 2016 World Series Champion, Olympic bronze medalist, founder of 400 Ventures, and minority owner of AFC Bournemouth and Lorient FC.
  • Valor Platform Focus: Transdermal peptide delivery targeting the anatomical ecosystem (tendons, ligaments, fascia, vasculature) to support site-directed signaling, tissue repair, accelerated recovery, and pain mitigation.
  • Target Market: Professional athletes, amateurs, weekend warriors, and sports medicine professionals.
  • Company Context: Valor operates as a division of Vector Science & Therapeutics Corp. (TSXV: PAIN), utilizing the company's pharmaceutical-grade peptide portfolio and cGMP manufacturing capabilities in Mequon, Wisconsin.

Notable Quotes

  • Dexter Fowler, Chair, Athlete Advisory Board, Valor: "Professional sports is repetitive stress at full intensity, every day. The same swing, the same sprint, the same throw…until the soft tissue that makes it possible breaks down faster than it can recover. That's not an injury. That's the job. Athletes deserve better options. That's why I'm here."
  • Darryl Drake Jr., President, Valor: "Soft tissue injuries that end careers rarely arrive without warning. They accumulate. Dexter has lived that. His voice opens doors no clinical argument alone can."
Read the original news release →

More from Vector Science and Therapeutics Corp.

Jun 30, 2026 · 08:55

Vector Science files provisional patent for magnetic transdermal peptide delivery, targeting De Novo FDA pathway amid rapid pipeline expansion.

M&A / Property Jun 22, 2026 · 07:40

From penny-stock SPAC shell to peptide-play: Vector Science bets on sports-medicine branding and cGMP manufacturing to monetize an $80B market.

M&A / Property Jun 08, 2026 · 07:50

Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor

Management Jun 02, 2026 · 07:45

Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy

Management May 13, 2026 · 10:48

Vector Science Secures Manufacturing Access Amid Related-Party Scrutiny

Other May 11, 2026 · 08:50

Vector swaps $6M capex for a cGMP key, unlocking shelf-stable peptides and signaling a manufacturing-first game plan.

Other